Clinical Trial Update: A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bardoxolone methyl in rare chronic kidney diseases has completed, with results posted January 18, 2022. Diseases studied include IgA ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease
• Chronic Kidney Disease Associated with Type Diabetes
• Focal Segmental Glomerulosclerosis
• Iga Nephropathy

Drugs mentioned

• Bardoxolone Methyl (bardoxolone methyl)

Snippet

Sponsor: Biogen | Conditions: IgA Nephropathy, CKD Associated With Type 1 Diabetes | Phase 2 | Status: COMPLETED | Results posted: 2022-01-18